Compare Tango Therapeutics Inc. (TNGX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Verizon Communications Inc — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while Verizon Communications Inc trades at $44.86 (market cap $180.86B). The key difference: Verizon Communications Inc is far larger — about 48.2× Tango Therapeutics Inc.'s market cap, and Verizon Communications Inc pays a 6.5% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Verizon Communications Inc for 109 Days on average.
| TNGX | VZ | |
|---|---|---|
Market Cap | $3.75B | $180.86B |
Volume | 9,619,106 | 30,427,702 |
Sector | Health | Media |
52-Week High | $32.90 | $51.45 |
52-Week Low | $7.50 | $38.40 |
Typical Hold Time | 0 Days | 109 Days |
Enterprise Value | $2.77B | $367.56B |
Dividend Yield | — | 6.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Verizon (VZ) trades at $44.42, up 3.83% today, with a bearish technical signal but strong fundamentals including a P/E of 11.34 and a 15.63% ROE. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results due October 26, 2026. Recent news highlights its joint venture with AT&T and T-Mobile to expand satellite connectivity and a steady dividend of $0.71 payable November 2, 2026.
The outlook is mixed: low valuation and consistent cash flow support income appeal, but technical weakness and modest revenue growth pose near-term risks. Analyst consensus leans hold with a $47.83 price target, suggesting limited upside. Key risks include competitive pressures and high debt levels, though strong operational cash flow provides stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
